Fresenius Medical Care AG

As of June 30, 2026, Fresenius Medical Care AG carries a market capitalization of 10.50B, placing it among publicly traded companies globally. Its enterprise value stands at 20.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fresenius Medical Care AG's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Fresenius Medical Care AG has 266.11M shares outstanding.

As of June 30, 2026, Fresenius Medical Care AG trades at a trailing price-to-earnings ratio of 11.79. The price-to-sales ratio is 0.57, and the price-to-book ratio stands at 0.84.

As of June 30, 2026, Fresenius Medical Care AG trades at an EV/EBITDA multiple of 6.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Fresenius Medical Care AG trades at an EV/FCF ratio of 10.05, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 20.98B versus a market cap of 10.50B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Fresenius Medical Care AG maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 81.02, indicating elevated leverage, while an interest coverage ratio of 8.82 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG posted a return on equity (ROE) of 7.26, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.74 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.00, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.98, useful for judging operating efficiency across full business cycles. The company generates approximately 173,878.96 in revenue per employee across its workforce of 111,728.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.61 indicates how many times Fresenius Medical Care AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG recorded 314.25M in income tax expense. That works out to an effective tax rate of 20.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.50B, leaving 937.78M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Fresenius Medical Care AG's stock has declined approximately 16.58% over the past 52 weeks. The 50-day moving average sits at 39.20, while the 200-day moving average is 39.39.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG generated 19.43B in revenue and converted that into 937.78M in net income, yielding earnings per share of 4.23. EBITDA reached 3.38B, while operating income came in at 1.96B.

As of June 30, 2026, Fresenius Medical Care AG holds 1.45B in cash and equivalents against 10.96B in total debt, resulting in a net debt position of 6.50B. Total book value stands at 12.56B, with working capital of 511.74M providing operational flexibility.

Fresenius Medical Care AG produced 2.83B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.05B in capital expenditures, free cash flow totaled 1.78B - equivalent to 6.36 per share.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG posted a gross margin of 26.36, reflecting its pricing power and cost economics. The operating margin of 10.11 and net profit margin of 4.83 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 16.14, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 24.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Fresenius Medical Care AG shareholders.

Fresenius Medical Care AG's most recent stock split took place on June 18, 2007 with a 1:3 split ratio.

As of June 30, 2026, Fresenius Medical Care AG has an Altman Z-Score of 3.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.